Clinical Trials /

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

NCT02414165

Description:

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD

Related Conditions:
  • Glioma
Recruiting Status:

Active, not recruiting

Phase:

Phase 2/Phase 3

Trial Eligibility

Document

Title

  • Brief Title: The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma
  • Official Title: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Clinical Trial IDs

  • ORG STUDY ID: Tg 511-15-01
  • SECONDARY ID: FD-R-5732
  • NCT ID: NCT02414165

Conditions

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma

Interventions

DrugSynonymsArms
Toca 511vocimagene amiretrorepvec, RRV, retroviral replicating vectorToca 511/Toca FC
Toca FCflucytosine, 5-FC, 5-fluorocytosineToca 511/Toca FC
LomustineCCNU, CeeNULomustine, Temozolomide, or Bevacizumab
TemozolomideTemodarLomustine, Temozolomide, or Bevacizumab
BevacizumabAvastinLomustine, Temozolomide, or Bevacizumab

Purpose

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC). Stratification will be done by IDH1 mutation status. A second stratification factor is based on the patient's Karnofsky Performance Score (KPS) (70-80 vs 90-100). Further, to account for potential differences in treatment choices for the control arm in regions, the trial will be stratified by geographical region during the randomization process. Funding Source - FDA OOPD

Trial Arms

NameTypeDescriptionInterventions
Toca 511/Toca FCExperimentalResection followed by administration of 4 mL Toca 511 (vocimagene amiretrorepvec). Toca 511 is administered by injection into the wall of the subject's tumor resection cavity on Day 1 (approximately 40 injections of 0.1 mL) Toca FC is an extended-release formulation of flucytosine. Toca FC will be administered at 220 mg/kg/day orally for 7-day courses beginning at least 6 weeks after resection and repeated approximately every 6 weeks.
  • Toca FC
Lomustine, Temozolomide, or BevacizumabActive ComparatorInvestigator selects one of the following: Bevacizumab: Beginning 6 weeks after tumor resection, bevacizumab will be administered by IV infusion at 10 mg/kg and repeated every 2 weeks. Refer to the prescribing information and to institutional guidelines for details on the administration procedure. Lomustine: Beginning 6 weeks after tumor resection, lomustine will be administered as a single oral dose of 110 mg/m2 and repeated every 6 weeks. Refer to the prescribing information and to institutional guidelines for details regarding the administration procedure. Temozolomide: Beginning 6 weeks after tumor resection, temozolomide will be administered per 1 of 2 options: at a dose of 50 mg/m2 PO once daily continuously, or at an initial dose of 150 mg/m2 IV or PO once daily for 5 consecutive days per 28-day treatment cycle that may be raised to 200 mg/ m2 once daily for 5 consecutive days in the following 28-day treatment cycles
  • Lomustine
  • Temozolomide

Eligibility Criteria

        Inclusion Criteria:

          1. Subject has given written informed consent

          2. Subject is between 18 years old and 75 years old, inclusive

          3. Subjects must have histologically proven GBM or AA and:

               1. Must have received first-line multimodal therapy with surgery followed by
                  temozolomide (unless MGMT promoter unmethylated) and radiation (subjects with GBM
                  must have received temozolomide and radiation concurrently)

               2. Must be in first or second recurrence (including this recurrence)

               3. Recurrence must be confirmed by diagnostic biopsy with local pathology review or
                  contrast-enhanced MRI. If first recurrence of GBM is documented by MRI, an
                  interval of at least 12 weeks after the end of prior radiation therapy is
                  required unless there is either: i) histopathologic confirmation of recurrent
                  tumor, or ii) new enhancement on MRI outside of the radiotherapy treatment field

          4. Subjects must have measurable disease preoperatively, defined as at least 1
             contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per
             RANO criteria

          5. Subjects must be at least 4 weeks post last dose of temozolomide

          6. Prior gamma knife, stereotactic radiosurgery, or other focal high-dose radiotherapy is
             allowed but the subject must have either histopathologic confirmation of recurrent
             tumor, or new enhancement on MRI outside of the radiotherapy treatment field

          7. Based on the pre-operative evaluation by neurosurgeon, the subject is a candidate for
             ≥ 80% resection of enhancing region

          8. IDH mutation status of the primary tumor must be available or tumor samples must be
             available for pre randomization testing

          9. Laboratory values adequate for patient to undergo surgery, including:

               -  Platelet count ≥ 60,000/mm3

               -  Hgb ≥ 10 g/dL

               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3

               -  Absolute lymphocyte count (ALC) ≥ 500/mm3

               -  Adequate liver function, including:

                    -  Total bilirubin ≤ 1.5 x ULN (unless has Gilbert's syndrome)

                    -  ALT ≤ 2.5 x ULN f. Estimated glomerular filtration rate of at least 50
                       mL/min by the Cockcroft Gault formula

         10. Women of childbearing potential (≥12 months of non-therapy-induced amenorrhea or
             surgically sterile) must have had a negative serum pregnancy test within the past 21
             days and must use a birth control method in addition to barrier methods (condoms).

         11. Subject or subject's partner is willing to use condoms for 12 months after receiving
             Toca 511 or until there is no evidence of the virus in his/her blood, whichever is
             longer.

         12. The subject has a KPS ≥ 70

         13. The subject is willing and able to abide by the protocol

        Exclusion Criteria:

          1. History of more than 2 prior recurrences (including this recurrence) of GBM or AA

          2. History of other malignancy, unless the patient has been disease free for at least 5
             years. Adequately treated basal cell carcinoma or squamous cell skin cancer is
             acceptable regardless of time, as well as localized prostate carcinoma or cervical
             carcinoma in situ after curative treatment

          3. Histologically confirmed oligodendroglioma or mixed glioma

          4. Known 1p/19q co deletion

          5. A contrast enhancing brain tumor that is any of the following:

               -  Multi focal (defined as 2 separate areas of contrast enhancement measuring at
                  least 1 cm in 2 planes that are not contiguous on either fluid attenuated
                  inversion recovery (FLAIR) or T2 sequences);

               -  Associated with either diffuse subependymal or leptomeningeal dissemination; or

               -  > 5 cm in any dimension

          6. The subject has or had any active infection requiring systemic antibiotic, antifungal
             or antiviral therapy within the past 4 weeks

          7. The subject has any bleeding diathesis, or must take anticoagulants, or antiplatelet
             agents, including nonsteroidal anti inflammatory drugs (NSAIDs), at the time of the
             scheduled resection that cannot be stopped for surgery

          8. The subject is human immunodeficiency virus (HIV) positive

          9. The subject has a history of allergy or intolerance to flucytosine

         10. The subject has a gastrointestinal disease that would prevent him or her from being
             able to swallow or absorb flucytosine

         11. The subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for
             nitrosoureas) of the planned surgery date

         12. The subject received any investigational treatment within the past 30 days or prior
             immunotherapy or antibody therapy within the past 45 days.

         13. The subject is pregnant or breast feeding

         14. The subject intends to undergo treatment with the Gliadel® wafer at the time of this
             surgery or has received the Gliadel® wafer < 30 days from W1D1 (surgery)

         15. The subject has received bevacizumab for their disease unless in the context of
             primary therapy for newly diagnosed glioma

         16. For subjects planned to potentially receive bevacizumab, they have no evidence of
             uncontrolled hypertension (defined as a blood pressure of ≥ 150 mm Hg systolic and/or
             ≥ 100 mm Hg diastolic on medication) or active GI perforation

         17. The subject has received systemic dexamethasone continuously at a dose > 8 mg/day for
             8 weeks prior to the date of the screening assessment

         18. Severe pulmonary, cardiac or other systemic disease, specifically:

               -  New York Heart Association > Grade 2 congestive heart failure within 6 months
                  prior to study entry, unless asymptomatic and well controlled with medication

               -  Uncontrolled or significant cardiovascular disease, clinically significant
                  ventricular arrhythmia (such as ventricular tachycardia, ventricular
                  fibrillation, or Torsades des pointes), clinically significant pulmonary disease
                  (such as ≥ Grade 2 dyspnea, according to CTCAE 4.03)

               -  Subjects who have any other disease, either metabolic or psychological, which as
                  per Investigator assessment may affect the subject's compliance or place the
                  subject at higher risk of potential treatment complications
      
Maximum Eligible Age:75 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:To compare the overall survival (OS) of subjects treated with Toca 511 combined with Toca FC to subjects treated according to standard of care after tumor resection for recurrence of glioblastoma or anaplastic astrocytoma
Time Frame:30 December 2019
Safety Issue:
Description:Time from randomization date to death due to any cause

Secondary Outcome Measures

Measure:Durable Response Rate (CR or PR ≥ 24 weeks)
Time Frame:30 December 2019
Safety Issue:
Description:The proportion of patients whose best response is either CR or PR lasting at least 24 weeks, according to modified RANO criteria
Measure:Durable Clinical Benefit Rate (CR or PR ≥ 24 weeks or SD ≥ 18 months)
Time Frame:30 December 2019
Safety Issue:
Description:The proportion of subjects whose best overall response is either CR or PR lasting at least 24 weeks, or stable disease (SD) lasting at least 18 months, according to modified RANO criteria
Measure:Duration of Durable Response
Time Frame:30 December 2019
Safety Issue:
Description:Time from documentation of durable response to disease progression or death due to disease progression
Measure:Overall Survival at 12 months
Time Frame:30 December 2019
Safety Issue:
Description:Time from randomization date to death due to any cause

Details

Phase:Phase 2/Phase 3
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:Tocagen Inc.

Trial Keywords

  • Recurrence

Last Updated

March 2, 2018